Company profile
Altimmune, Inc.
NASDAQ: ALT · Healthcare · Biotechnology
#1087 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
55CFH 44DQ 65GM 63SS 59
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$36.0k
Rev growth YoY (TTM)
+80.0%
Net income (FY)
-$88.1M
Employees
57
as of 2026-08-13
Market cap
$569.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$41.0k$41.0k2025
Net income-$88.1M-$88.1M2025
Operating income-$94.5M-$94.5M2025
Total assets$279.9M$279.9M2025
Liabilities$55.0M$55.0M2025
Equity$224.9M$224.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2021
By product
Grant100%
By geography
Not disclosed.
The read
What is Altimmune, Inc.’s revenue?
Altimmune, Inc. booked $41.0k in FY2025 revenue, growing 105% year over year — faster than most Healthcare companies we track, at a -214861.0% net margin.
Peers · Healthcare
DIAGNOS Inc.29DCalidi Biotherapeutics, Inc.19DMillennium Sustainable Ventures Corp.——Neonc Technologies Holdings, Inc.10DAXIM Biotechnologies, Inc.——AREV Life Sciences Global Corp——Neighbors
Montgomery →Key facts
CEOJerome Benedict Durso
SectorHealthcare
IndustryBiotechnology
HeadquartersGaithersburg, MD
ExchangeNASDAQ: ALT
Employees57
IPO date2017-05-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.